| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 440.29 | 7.9% |
| Total Income | 448.27 | 7.7% |
| Expenditure | 372.70 | 2.1% |
| PBT | 42.02 | 17.7% |
| Net Profit | 30.85 | 19.7% |
| OPM | 5.60% | 2.54pp |
| NPM | 6.88% | 2.35pp |
| EPS | 12.34 | 19.7% |
AstraZeneca Pharma India Achieves 44% Increase in Revenue in Q3 2024
12 Feb 2025 · 12 Feb 2025, 12:14 am
Summary
AstraZeneca Pharma India reported strong financial performance in Q3 2024, with a 44% increase in revenue compared to the same period last year. The total revenue from operations increased by Rs. 1,345 Mn compared to the corresponding quarter of the previous year. The Oncology business grew by 67%, the Biopharmaceutical business grew by 10%, and the rare disease business consistently increased its focus to help more patients with NF1.
Key Highlights
- 1
AstraZeneca Pharma India achieved a 44% increase in revenue in Q3 2024 compared to the same period last year
- 2
Total revenue from operations increased by Rs. 1,345 Mn compared to the corresponding quarter of the previous year
- 3
The Oncology business grew by 67% in Q3 2024
- 4
The Biopharmaceutical business grew by 10% in Q3 2024
- 5
The rare disease business consistently increased its focus to help more patients with NF1
Management Comments
Bhavana Agrawal
Chief Financial Officer & Director of the Company
Our Growth Through Innovation strategy is helping us achieve a robust growth in the country. Our Oncology business last quarter grew by 67%, Biopharmaceutical business grew by 10%, furthering efforts to deliver the next generation of therapeutics in our portfolio and pipeline, and our rare disease business is consistently increasing its focus to help more patients with NF1. Our operational excellence continues to strengthen company’s foundation to grow profitably as we are focussing Our focus on science and newer access strategies continues to enable us transform health outcomes for patients in the country
Dr. Sanjeev Panchal
Country President & Managing Director of the Company
Our aspiration to be pioneers in science has increased our focus on specialist disease areas where we can make the most meaningful difference in helping people with cancer, other chronic and rare disease. This quarter, we grew by 44% and this consistent progress is a derivative of unwavering commitment to address unmet patient needs while delivering innovative medicines faster to patients in India. We are focused on increasing access to healthcare and making healthcare systems more resilient while contributing sustainably to people, society and the planet
Informational and educational content only. Not investment advice.